LCTX icon

Lineage Cell Therapeutics

0.4298 USD
+0.0298
7.45%
At close Apr 22, 4:00 PM EDT
After hours
0.4350
+0.0052
1.21%
1 day
7.45%
5 days
-2.52%
1 month
-19.86%
3 months
-36.33%
6 months
-51.47%
Year to date
-16.54%
1 year
-62.30%
5 years
-41.25%
10 years
-52.67%
 

About: Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Employees: 77

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

153% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 15

108% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 13

9% more funds holding

Funds holding: 114 [Q3] → 124 (+10) [Q4]

1.5% less ownership

Funds ownership: 50.08% [Q3] → 48.58% (-1.5%) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

37% less capital invested

Capital invested by funds: $85.6M [Q3] → $53.8M (-$31.8M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$2
365%
upside
Avg. target
$4.67
986%
upside
High target
$9
1,994%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
B. Riley Securities
Mayank Mamtani
9% 1-year accuracy
2 / 22 met price target
598%upside
$3
Buy
Maintained
14 Mar 2025
D. Boral Capital
Jason Kolbert
19% 1-year accuracy
70 / 359 met price target
365%upside
$2
Buy
Maintained
11 Mar 2025
HC Wainwright & Co.
Joseph Pantginis
15% 1-year accuracy
62 / 417 met price target
1,994%upside
$9
Buy
Reiterated
11 Mar 2025

Financial journalist opinion

Neutral
Business Wire
11 hours ago
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to collaborate and present the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). This ye.
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
Neutral
Business Wire
1 day ago
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, has been invited to join presenters from REGENXBIO Inc., Regenerative Patch Technologies, LLC, Neurotech Pharmaceuticals, Inc., and others, as part of the “I Shall Be Released: Novel Drug Delivery Approaches for Glaucoma and R.
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)
Neutral
Seeking Alpha
1 month ago
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants Jack Allen - Baird Joseph Pantginis - H.C. Wainwright Michael Okunewitch - Maxim Group Mayank Mamtani - Riley Securities Albert Lowe - Craig-Hallum Sean McCutcheon - Raymond James Operator Thank you for standing by.
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript
Neutral
Business Wire
1 month ago
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today reported its fourth quarter and full year 2024 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. “Throughout 2024, we made substantial progress across multiple fronts, advancing o.
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Neutral
Business Wire
1 month ago
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m.
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
Neutral
Business Wire
2 months ago
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, announced today that the Company has initiated the DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. The DOSED study will evaluate the safety and utility of the Manual Inject Parenchymal Spinal Delivery Syste.
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
Neutral
Business Wire
2 months ago
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Lifesciences Conference on February 11, 2025 at 12:40pm ET. The conference is being held virtually February 11-12, 2025. Interested parties can view a re.
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
Positive
24/7 Wall Street
2 months ago
Insiders Are Scooping Up These 5 Stocks Now
Since the beginning of the year, the number of notable insider purchases has been lower than usual.
Insiders Are Scooping Up These 5 Stocks Now
Positive
Zacks Investment Research
2 months ago
Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Lineage Cell (LCTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Neutral
Business Wire
2 months ago
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously announced registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 million in gross proceeds at the closing of the first tranche in November 2024. Today, the Company received an addit.
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
Charts implemented using Lightweight Charts™